Combination therapy using an il-1 inhibitor for treating...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/06 (2006.01) A61K 38/20 (2006.01)

Patent

CA 2273852

The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6- pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.

L'invention porte sur des méthodes de traitement ou de prévention de l'arthrite consistant à administrer à des patients qui le nécessitent une dose à effet thérapeutique d'un inhibiteur de l'IL-1 et de méthotréxate. Dans une variante préférée, l'inhibiteur de l'IL-1 est un inhibiteur humain IL-1ra de recombinaison, et le méthotréxate, de l'acide N-[4-[(2,4-diamino-6-ptéridinyl)méthylamino]benzoyl]-L-glutamique. L'invention porte également sur des préparations pharmaceutiques contenant un inhibiteur de l'IL-1 et du méthotréxate et s'utilisant dans lesdites méthodes.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combination therapy using an il-1 inhibitor for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy using an il-1 inhibitor for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using an il-1 inhibitor for treating... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1403287

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.